Physician
Gulf Coast Pain Consultants LLC
Gulf Coast Pain Consultants LLC was paid $614K by Medicaid between Jan 2018 and Dec 2024, across 29 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 59% of everything it billed.
33Billing provider infoGULF COAST PAIN CONSULTANTS LLC
PENSACOLA, FL 32504
PENSACOLA, FL 32504
33aNPI1669712287assigned 02/19/2013
33bProvider typeInterventional Pain Medicine Physician
28Total paid$614K
24GClaims76,645
24DCodes billed29
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Florida
Rank by total paid#4 of 56
Median peer was paid$7K
This provider vs. median84×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,589 | $5K | |
| 2019 | 6,828 | $68K | |
| 2020 | 8,011 | $85K | |
| 2021 | 10,701 | $100K | |
| 2022 | 14,305 | $105K | |
| 2023 | 20,617 | $127K | |
| 2024incomplete | 10,594 | $123K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 59% | 33,442 | 22,524 | $363K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 33% | 33,319 | 23,087 | $202K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.5% | 571 | 454 | $21K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 1,724 | 1,425 | $10K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.1% | 657 | 553 | $7K |
| 64493 | <1% | 155 | 57 | $5K | |
| 64494 | <1% | 157 | 57 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,166 | 830 | $1K |
| 99152 | <1% | 475 | 363 | $995.40 | |
| 62323 | <1% | 32 | 12 | $711.78 | |
| 64495 | <1% | 34 | 12 | $685.84 | |
| 64635 | <1% | 16 | 12 | $650.67 |
17 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 829 | $331.30 |
| 64636 | <1% | 18 | $240.63 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,015 | $196.88 |
| 99205 | Prolong outpt/office vis | <1% | 27 | $154.98 |
| 95886 | <1% | 26 | $150.62 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 738 | $111.47 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 98 | $0.00 |
| 1036F | 0% | 399 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 16 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 27 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 28 | $0.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 124 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 547 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 549 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 423 | $0.00 |
| L0650 | Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf | 0% | 14 | $0.00 |
| 4004F | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMONTGOMERY, KACEY (REGIONAL MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Interventional Therapeutics Institute, LLC | Pensacola, FL | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.